Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JR-142 versus GROWJECT in Japanese children with short stature born small for gestational age
jRCT2031260474Phase 3Recruiting
- Sponsor
- JCR Pharmaceuticals
- Start
- Oct 2026
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of redalsomatropin alfa in Short stature in children born small for gestational age (2 arms), sponsored by JCR Pharmaceuticals. Primary endpoint: Change in height SDS for chronological age from baseline at Week 52. Started Oct 2026; status: recruiting.
02
Drugs
redalsomatropin alfa
03
Conditions
Short stature in children born small for gestational age
Beyond the preview
Go deeper on jRCT2031260474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260474.